Want to join the conversation?
$CAH 4Q15 Call: We finished Fiscal 2015 with a very strong fourth quarter. Revenues increased 20%, non-GAAP operating earnings increased 33% and we reported non-GAAP EPS of $1.00. Harvard Drug strengthens our capabilities in generics and marketing reach.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)